China: Restrictions And Conflicts – Challenges Faced By Pharmaceutical Trademarks In China

Last Updated: 6 November 2019
Article by Sarah Song

Trademarks represent one of the most essential competitive and strategic assets of a company. When considering how consumers identify their choices among other alternatives, trademarks are key. Because pharmaceutical products play an important role in public healthcare, the protection of pharmaceutical trademarks brings special challenges, particularly when it comes to a pharmaceutical product's name, generic name and public interest.

Restrictions on registration

According to the relevant law, the registration of pharmaceutical trademarks has numerous restrictions. Pharmaceutical trademarks should have distinctive features and must not conflict with any pre-existing lawful rights of others in order to qualify for registration. When a pharmaceutical trademark is only a direct representation of the quality, primary raw materials, functions, intended purpose, weight, quantity or other characteristics of the relevant pharmaceutical product, the China Trademark Office will reject registration based on the mark "lacking distinctive features". In spite of this, there are cases where such pharmaceutical trademarks have been approved for registration where they have acquired distinctiveness through the registrant's use.

A pharmaceutical trademark should not conflict with another's pre-existing copyright, trademark right or any other interests protected by Chinese law. When it comes to pharmaceutical marks, the Trademark Office will also consider whether the applied-for mark conflicts with another party's pre-existing pharmaceutical product name.

If the applied-for mark violates Article 10 of the Trademark Law, the Trademark Office will reject the application. Signs that are prohibited from being registered as pharmaceutical marks in the Chinese market include:

    - trademarks which discriminate against nationality, race or religion, among others;

    - marks identical or similar to the name, sign or mark 'red cross' or 'red crescent';

    - marks that are deceptive and likely to cause public confusion in terms of the quantity, other characteristics or place of production of the relevant goods; and

    - marks which, according to Chinese culture, are detrimental to socialist morality and customs.

Any use of a pharmaceutical trademark in the Chinese market in violation of the above may be subject to a fine of up to 20% of the company's revenue.

If a pharmaceutical trademark has been recognised as the generic name of the relevant pharmaceutical products, the Trademark Office will not accept an application for that mark. In practice, even where a pharmaceutical mark is not a generic name when the trademark application is submitted, the Trademark Office will still not grant the trademark right if the examiner observes that the mark in question has become a generic name during the reviewing term. Likewise, if a pharmaceutical trademark was a generic name when the application was filed, but is no longer one by the time that the registration is processed, the Trademark Office will not be prejudiced against such a registration.

Restrictions on use

First, according to the relevant regulations, pharmaceutical trademarks that have not been registered before the Trademark Office cannot be used in package inserts and product labels – until the registrant obtains the relevant trademark registration certificate, the authorities regard it as unregistered. Registered pharmaceutical trademarks should be printed on a corner of the drug's product label. When using a pharmaceutical trademark that includes words, the font should be a quarter of the size, or smaller, of the font used for the generic name of the relevant pharmaceutical product.

Second, according to a notice issued by the State Food and Drug Administration in 2006, the advertising of any pharmaceutical trademarks that have not been registered is prohibited. A pharmaceutical trademark used to advertise a drug must be used together with the drug's generic name. When using the mark in textual and television advertisements, the font type used for a word-based pharmaceutical trademark should be calculated based on the area of a single word and must not exceed a quarter of the size of the font used by the generic name of the relevant pharmaceutical product.

Registrants of any pharmaceutical trademark should also pay attention to the provisions of the Trademark Law. For example, the registrant should not, without authorisation, make changes to the registered pharmaceutical trademark, the name or address of the registrant or other registration items during the course of using the registered pharmaceutical trademark.

Coexistence and conflict

Pharmaceutical products sold in the Chinese market may have a pharmaceutical trademark, product name and a generic name used on the labels and package inserts.

The pharmaceutical product name and generic name are regulated by the Food and Drug Administration, while the pharmaceutical trademark is regulated by the Trademark Office. Given these separate and distinct authorities, the coexistence of pharmaceutical product names and pharmaceutical trademarks has caused conflict.

Pharmaceutical trademarks and generic names

In China, the generic names of pharmaceutical products include statutory generic names and conventional generic names. According to the relevant regulations, the statutory generic name of a pharmaceutical product is formulated and revised by a pharmacopoeia commission under the Drug Regulatory Authority in accordance with the national drug standards, which is listed in the Pharmacopoeia of the People's Republic of China and other drug standards published by the authority. In order to identify pharmaceutical products with the same ingredients or formulae, it is mandatory to indicate the generic name of the pharmaceutical product. The conventional generic name refers to a name that signifies to the relevant public certain kinds of pharmaceutical. If the name of the pharmaceutical product is listed in professional reference books and dictionaries, the Trademark Office will use it as an important reference to determine conventional generic names. Conventional generic names are usually determined according to the general perception of the relevant public nationwide.

If a pharmaceutical trademark is recognised as a generic name, the Trademark Office will not approve it for registration. Further, even if the pharmaceutical trademark was not a generic name when the trademark Office approved the  registration, and the registered trademark became a generic name due to the pharmaceutical companies' improper use of it or for other reasons, according to the Trademark Law, anyone is entitled to apply to the Trademark Office for the cancellation of such a mark. One of the most famous examples of such a degraded trademark is Bayer's painkiller brand Aspirin, which has been recognised as a generic name in many countries and has been used widely in the pharmaceutical industry.

The degradation of a registered pharmaceutical trademark into a generic name can be the result of, among other things, the following:

    - the trademark itself is not distinct enough;

    - the new pharmaceutical name is too professional, lengthy and complicated to be accepted by the consumer;

    - the authorities mistakenly published the pharmaceutical trademark as its product name;

    - the owner or an infringer promoted the pharmaceutical trademark improperly; and

    - the pharmaceutical trademark has commanded a monopoly in the relevant market for a long time.

Pharmaceutical trademarks and pharmaceutical product names

Before a pharmaceutical product name is approved for use, it goes through an examination procedure by the drug administrative authorities. During the procedure, the authorities will examine whether the name to be registered is the same as or similar to any pre-existing name. After approval for the pharmaceutical product name is obtained, the applicant can exclude others from using the same or similar names on the same pharmaceutical product. In another words, the applicant enjoys a certain legal interest in the pharmaceutical product name after examination and approval. Therefore, based on Supreme Court case law, if a pre-existing pharmaceutical product name was used prominently after approval and obtained a degree of influence in the market, it will be protected by the Trademark Law. Consequently, under certain conditions, a pre-existing pharmaceutical product name may prevail over a registered pharmaceutical trademark in China.

According to the relevant regulations issued by the Food and Drug Administration, since 2006 only pharmaceutical products with a new chemical structure or new active ingredients, as well as new pharmaceutical products that have been officially granted a patent of a compound, may apply for a pharmaceutical product name before the administration. However, pharmaceutical companies may continue to use pharmaceutical product names that were approved before 1 June 2006.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions